• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本糖尿病致盲患者的特征。

Characterization of the visually impaired patients with diabetes mellitus in Japan.

机构信息

J-CREST (Japan Clinical REtina STudy group), Kagoshima, Japan.

Department of Ophthalmology, Faculty of Medical Sciences, University of Fukui, Yoshida, Japan.

出版信息

J Diabetes Investig. 2024 Jul;15(7):882-891. doi: 10.1111/jdi.14195. Epub 2024 Mar 27.

DOI:10.1111/jdi.14195
PMID:38534040
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11215670/
Abstract

AIMS/INTRODUCTION: To conduct a multicenter survey of visually impaired patients with diabetes mellitus (DM) and to identify the physical and ocular characteristics that lead to blindness in Japan.

MATERIALS AND METHODS

Visually impaired patients with diabetes mellitus in Japan were divided into blind and low-vision groups according to the World Health Organization classification. Data on parameters related to diabetes mellitus and ocular complications in the right and left eyes were collected from 19 highly advanced medical facilities and compared between the two groups.

RESULTS

Among 408 visually impaired persons (blind group: 257, low-vision group: 151), 72.1% were under 70 years of age. The rates of neovascular glaucoma (NVG) (right eye, P = 0.041; left eye, P = 0.0031) or proliferative diabetic retinopathy (PDR) (right eye: P = 0.014, left eye: P = 0.0047) and the rate of proliferative membrane beyond half of the retinal area (right eye: P = 0.0263, left eye: P = 0.037) were significantly higher in the blind group. The direct cause of visual impairment was retinal atrophy, common in both groups. Neovascular glaucoma and diabetic macular edema were equally prevalent in the blind and low-vision groups, respectively.

CONCLUSIONS

In Japan, blind patients with diabetes mellitus are characterized by severe conditions such as neovascular glaucoma and progressive proliferative diabetic retinopathy upon their initial visit to an advanced care facility. These results highlight the importance of monitoring retinopathy through regular ophthalmological examinations, internal medicine, and appropriate therapeutic intervention.

摘要

目的/引言:对日本的糖尿病致盲患者进行多中心调查,明确导致其失明的身体和眼部特征。

材料和方法

根据世界卫生组织的分类,将日本的糖尿病致盲患者分为盲和低视力组。从 19 家高度先进的医疗机构收集了右眼和左眼与糖尿病和眼部并发症相关的参数数据,并对两组数据进行了比较。

结果

在 408 名视力受损者(盲组:257 人,低视力组:151 人)中,72.1%年龄在 70 岁以下。新生血管性青光眼(NVG)(右眼,P=0.041;左眼,P=0.0031)或增生性糖尿病视网膜病变(PDR)(右眼:P=0.014,左眼:P=0.0047)的发生率以及增生性膜超过视网膜面积一半的发生率(右眼:P=0.0263,左眼:P=0.037)在盲组中明显更高。两组中视力损害的直接原因均为视网膜萎缩。新生血管性青光眼和糖尿病性黄斑水肿在盲组和低视力组中的发病率相当。

结论

在日本,初次就诊于高级医疗机构的糖尿病致盲患者病情严重,存在新生血管性青光眼和进行性增生性糖尿病视网膜病变等情况。这些结果强调了通过定期眼科检查、内科治疗和适当的治疗干预来监测视网膜病变的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/3c793e7e84d3/JDI-15-882-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/8e88c96549b9/JDI-15-882-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/1f7967bcbecc/JDI-15-882-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/6ed715951f9f/JDI-15-882-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/ef94d9336284/JDI-15-882-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/000ae7f6ee87/JDI-15-882-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/5e1c204847e9/JDI-15-882-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/3c793e7e84d3/JDI-15-882-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/8e88c96549b9/JDI-15-882-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/1f7967bcbecc/JDI-15-882-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/6ed715951f9f/JDI-15-882-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/ef94d9336284/JDI-15-882-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/000ae7f6ee87/JDI-15-882-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/5e1c204847e9/JDI-15-882-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69be/11215670/3c793e7e84d3/JDI-15-882-g004.jpg

相似文献

1
Characterization of the visually impaired patients with diabetes mellitus in Japan.日本糖尿病致盲患者的特征。
J Diabetes Investig. 2024 Jul;15(7):882-891. doi: 10.1111/jdi.14195. Epub 2024 Mar 27.
2
Diabetic retinopathy. Screening and prevention of blindness. A doctoral thesis.糖尿病性视网膜病变。失明的筛查与预防。博士论文。
Acta Ophthalmol Scand Suppl. 1997(223):1-76.
3
Rapid assessment of avoidable blindness and diabetic retinopathy in Republic of Moldova.摩尔多瓦共和国可避免失明和糖尿病视网膜病变的快速评估。
Br J Ophthalmol. 2015 Jun;99(6):832-6. doi: 10.1136/bjophthalmol-2014-305824. Epub 2014 Dec 30.
4
Visual acuity in a population with regular screening for type 2 diabetes mellitus and eye disease.对2型糖尿病和眼部疾病进行定期筛查人群的视力情况
Acta Ophthalmol Scand. 2007 Feb;85(1):40-5. doi: 10.1111/j.1600-0420.2006.00753.x.
5
Visual impairment and blindness in type 2 diabetics: Ife-Ijesa diabetic retinopathy study.2型糖尿病患者的视力损害与失明:伊费-伊杰沙糖尿病视网膜病变研究。
Int Ophthalmol. 2016 Aug;36(4):477-85. doi: 10.1007/s10792-015-0145-8. Epub 2015 Nov 4.
6
Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study.北京城乡地区失明和视力损伤的病因:北京眼病研究
Ophthalmology. 2006 Jul;113(7):1134.e1-11. doi: 10.1016/j.ophtha.2006.01.035. Epub 2006 May 2.
7
Prevalence and causes of visual impairment in diabetic patients in Tunisia, North Africa.北非突尼斯糖尿病患者视力损害的患病率及病因
Eye (Lond). 2014 Aug;28(8):986-91. doi: 10.1038/eye.2014.131. Epub 2014 Jun 13.
8
The impact of diabetes on visual acuity in Ethiopia, 2021.2021 年埃塞俄比亚糖尿病对视力的影响。
PLoS One. 2021 Aug 13;16(8):e0256145. doi: 10.1371/journal.pone.0256145. eCollection 2021.
9
Diabetic retinopathy, visual impairment and ocular status among patients with diabetes mellitus in Yemen: a hospital-based study.也门糖尿病患者的糖尿病视网膜病变、视力障碍和眼部状况:一项基于医院的研究。
Indian J Ophthalmol. 2009 Jul-Aug;57(4):293-8. doi: 10.4103/0301-4738.53055.
10
Low vision in Nigerians with diabetes mellitus.尼日利亚糖尿病患者的低视力
Doc Ophthalmol. 2000 Jul;101(1):51-7. doi: 10.1023/a:1002799506855.

本文引用的文献

1
Long-term outcomes of Baerveldt glaucoma implant surgery in Japanese patients.贝伐单抗青光眼植入术治疗日本患者的长期疗效。
Sci Rep. 2023 Aug 31;13(1):14312. doi: 10.1038/s41598-023-41673-6.
2
A nationwide survey of newly certified visually impaired individuals in Japan for the fiscal year 2019: impact of the revision of criteria for visual impairment certification.2019 财年日本新认定视力障碍者的全国性调查:视力障碍认定标准修订的影响。
Jpn J Ophthalmol. 2023 May;67(3):346-352. doi: 10.1007/s10384-023-00986-9. Epub 2023 Apr 17.
3
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
faricimab 在日本糖尿病黄斑水肿患者中每 16 周延长给药的疗效、持久性和安全性:来自 3 期 YOSEMITE 试验日本亚组的 1 年结果。
Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10.
4
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.雀鹰和风筝研究:布罗鲁单抗治疗糖尿病性黄斑水肿两项III期关键试验的52周结果
Am J Ophthalmol. 2022 Jun;238:157-172. doi: 10.1016/j.ajo.2022.01.004. Epub 2022 Jan 14.
5
The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen.按需治疗方案中复发与再次注射间隔时间对糖尿病性黄斑水肿抗VEGF治疗的影响
J Clin Med. 2021 Dec 8;10(24):5738. doi: 10.3390/jcm10245738.
6
Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial.玻璃体腔内阿柏西普治疗日本新生血管性青光眼患者的随机临床试验(VEGA)
Adv Ther. 2021 Feb;38(2):1116-1129. doi: 10.1007/s12325-020-01579-5. Epub 2020 Dec 16.
7
Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study.2020 年失明和视力障碍的原因及 30 多年来的趋势,以及与 VISION 2020:看见的权利相关的可避免盲的患病率:全球疾病负担研究的分析。
Lancet Glob Health. 2021 Feb;9(2):e144-e160. doi: 10.1016/S2214-109X(20)30489-7. Epub 2020 Dec 1.
8
Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration.Brolucizumab:一种新型抗 VEGF 分子,用于治疗新生血管性年龄相关性黄斑变性。
Ophthalmologica. 2021;244(2):93-101. doi: 10.1159/000513048. Epub 2020 Nov 16.
9
Prognostic factors of revitrectomy for complications in eyes with proliferative diabetic retinopathy: a retrospective multicentre study.增殖性糖尿病视网膜病变患者行玻璃体切除术并发症的预后因素:一项回顾性多中心研究
Acta Ophthalmol. 2020 Jun;98(4):e434-e439. doi: 10.1111/aos.14292. Epub 2019 Nov 1.
10
Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals.日本视力障碍的发病率及病因:首次针对新认证视力障碍者的全国性全面普查
Jpn J Ophthalmol. 2019 Jan;63(1):26-33. doi: 10.1007/s10384-018-0623-4. Epub 2018 Sep 25.